Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE UNIQUE: Bimekizumab in Moderate to Severe Plaque Psoriasis
NCT06506916Phase 3Active, not recruiting
- Sponsor
- UCB
- Start
- Jul 2024
- Primary completion
- Mar 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 3 trial of bimekizumab in plaque psoriasis, psoriatic arthritis (PsA), sponsored by UCB. Started Jul 2024; status: active, not recruiting.
02
Drugs
bimekizumab
03
Conditions
plaque psoriasispsoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT06506916.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06506916.